PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Ferric Derisomaltose→

Ferric Derisomaltose PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
Not available
Molecular formula
Not available
Molecular weight
~150000 g/mol
Drug class
Intravenous ferric iron–carbohydrate complexparenteral iron replacement agent
Mechanism of action
A stable iron(III)-hydroxide complex with derisomaltose carbohydrate. After intravenous administration, iron is taken up by reticuloendothelial cells and released for transferrin binding, haemoglobin synthesis and replenishment of iron stores; it is not a simple iron salt.
Indications / reported uses
  • Treatment of iron-deficiency anaemia in adults who have intolerance to oral iron or have had an unsatisfactory response to oral iron
  • Use in adults with non-dialysis-dependent chronic kidney disease or other specified causes of iron deficiency according to the product label

Sources: US DailyMed — MONOFERRIC (ferric derisomaltose) · EMA EPAR — Monofer · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Ferric Derisomaltose PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Ferric Derisomaltose Permitted Daily Exposure (PDE) report (the Ferric Derisomaltose PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Ferric Derisomaltose Occupational Exposure Limit (OEL) report (the Ferric Derisomaltose OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.